The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

Geron Corporation's RYTELO gains FDA approval for Low-Risk MDS, with strong sales projections and promising Phase 3 study.

A 7-year-old in Idaho is at the forefront of many minds in the Lewisville area, as her family and community plan a fundraiser ...

Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS ...

Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) ...

Initial data from the Phase 1 trial expected in 2025SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the ...

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...

Shares were up 30% to 5.18 Canadian dollars Wednesday. Medexus will target a commercial launch in the first half of calendar 2025. The company believes product-level revenue in the U.S. has the ...

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...